GlaxoSmithKline's Flovent HFA asthma inhaler approved by FDA for use in children

By Angela McDaniels

Seattle, March 23 - GlaxoSmithKline plc said the Food and Drug Administration has approved the use of Flovent HFA for the prevention of airway inflammation associated with asthma in children four to 11 years of age.

Flovent HFA was approved by the FDA in May 2004 for patients 12 years of age and older and has since become the most prescribed inhaled corticosteroid for asthma, according to a company news release.

Flovent HFA is a reformulation of the asthma medication Flovent (fluticasone propionate) Inhalation Aerosol that uses hydrofluoroalkane to propel the medication out of the canister and into the lungs. Hydrofluoroalkane replaces the chlorofluorocarbon propellant and is more ozone friendly, the company said.

The U.S. Centers for Disease Control has estimated that 9 million children under the age of 18 have been diagnosed with asthma and 3.6 million of those children are between the ages of five and 11, according to the release.

GlaxoSmithKline is a pharmaceutical and health care company based in London.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.